American heart association conference

ARB fails to reduce heart failure deaths, trial shows.

Use of the angiotensin receptor blocker (ARB) irbesartan does not appear to reduce mortality rates in patients with heart failure (HF), US research suggests.

The findings, presented at the American Heart Association scientific sessions in New Orleans last week, highlight the need for better treatments for HF patients with preserved left ventricular ejection fraction.

Researchers randomly assigned 4,128 patients, aged 60 and over, to receive 300mg of irbesartan or placebo daily. All had HF and an ejection fraction of at least 45 per cent.

The patients were followed up for 49.5 months, during which time 742 people in the irbesartan group died, compared with 763 deaths in the placebo group. But this difference was not statistically significant.

Lead researcher Dr Barry Massie, from the Veterans Affairs Medical Centre, San Francisco, said that the trial failed to achieve its primary endpoint, a reduction of mortality.

'It had no significant impact on the secondary endpoints of hospitalisation for HF, stroke and MI,' he added.

'It is disappointing that there remains no specific evidencebased therapy for these patients.'

However, the researchers pointed out that the effects of ARBs in the trial may have been decreased by the fact that 25 per cent of patients involved were taking ACE inhibitors and 15 per cent were taking spironolactone, which affect the renin-angiotensin system.

In order for this field to move forward, a better understanding of the mechanisms underlying this syndrome and the potential targets for treatment are required, said Dr Massie.

Dr Margaret Redfield, from the Mayo Clinic in Minnesota, added: 'This was a very impor-tant trial. ARBs are commonly used in HF patients despite a lack of evidence.

'We need more studies to understand what is going on with these patients.'

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Almost 80% of people aged over 80 in the UK have have had at least one dose of COVID-19...

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Revalidation and ongoing fitness to practise cases will continue despite huge pressure...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Supporting men and children experiencing domestic violence through general practice

Supporting men and children experiencing domestic violence through general practice

IRIS is an evidence-based programme designed to reach female survivors of domestic...

Learn about neurological aspects of 'long COVID' at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID' at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of 'long COVID' infection will be...

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

The government must ‘ramp up’ COVID vaccine supplies to general practice and avoid...